Related Experiment Video

Updated: Jun 28, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK

Chaoyan Wang1,2,3, Bo Wang1,2,4, Yu Mou1,2,3

  • 1State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China.

Molecules (Basel, Switzerland)
|April 13, 2024
PubMed

Insights

A novel compound, H-120, effectively combats leukemia by inducing cancer cell death and halting cell cycle progression. This dianilinopyrimidine analog shows promise as a potential chemotherapeutic agent for leukemia treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Leukemia relapse remains a significant challenge despite advancements in chemotherapy.
  • There is a critical need for novel anti-leukemia compounds to improve patient outcomes.

Purpose of the Study:

  • To synthesize and evaluate novel dianilinopyrimidine analogs for anti-leukemia activity.
  • To investigate the mechanism of action of the most potent analog, H-120, in leukemia cells.

Main Methods:

  • Synthesis of a series of dianilinopyrimidines.
  • In vitro evaluation of anti-leukemia activity using HEL, Jurkat, and K562 cell lines.
  • Apoptosis assays, cell cycle analysis, Western blotting, and protein isolation assays.
  • In vivo study in erythroleukemia mouse models.

Main Results:

  • Dianilinopyrimidine analog H-120 exhibited significant cytotoxic potential against HEL cells.
  • H-120 induced apoptosis by modulating key apoptosis-related proteins and cell cycle arrest at G2/M.
  • H-120 inhibited STAT3 and c-Myc activation, phosphorylation, and dimerization.
  • In vivo, H-120 suppressed erythroleukemia progression, promoted erythroid differentiation, and improved liver function.

Conclusions:

  • H-120 demonstrates potent anti-leukemia effects through apoptosis induction and cell cycle arrest.
  • H-120's mechanism involves the inhibition of STAT3 and c-Myc signaling pathways.
  • H-120 shows therapeutic potential in preclinical models, suggesting its promise as a novel leukemia chemotherapeutic agent.
Keywords:
Ras/Raf/MER/ERKSTAT3/c-Mycapoptosisdianilinopyrimidinesleukemia

More Related Videos

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.6K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K